IL157881A0 - Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds - Google Patents

Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds

Info

Publication number
IL157881A0
IL157881A0 IL15788102A IL15788102A IL157881A0 IL 157881 A0 IL157881 A0 IL 157881A0 IL 15788102 A IL15788102 A IL 15788102A IL 15788102 A IL15788102 A IL 15788102A IL 157881 A0 IL157881 A0 IL 157881A0
Authority
IL
Israel
Prior art keywords
aryl
preparation
substituted indenes
fused azapolycyclic
azapolycyclic compounds
Prior art date
Application number
IL15788102A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL157881A0 publication Critical patent/IL157881A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL15788102A 2001-04-20 2002-03-04 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds IL157881A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28513101P 2001-04-20 2001-04-20
PCT/IB2002/000660 WO2002085843A2 (en) 2001-04-20 2002-03-04 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
IL157881A0 true IL157881A0 (en) 2004-03-28

Family

ID=23092860

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15788102A IL157881A0 (en) 2001-04-20 2002-03-04 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds

Country Status (25)

Country Link
US (2) US7091372B2 (ko)
EP (1) EP1383733B1 (ko)
JP (1) JP2004527545A (ko)
KR (1) KR100551183B1 (ko)
CN (1) CN1321107C (ko)
AR (2) AR035957A1 (ko)
AT (1) ATE388135T1 (ko)
AU (1) AU2002234836B2 (ko)
BR (1) BR0208992A (ko)
CA (1) CA2443946A1 (ko)
CZ (1) CZ20032814A3 (ko)
DE (1) DE60225433T2 (ko)
DK (1) DK1383733T3 (ko)
ES (1) ES2300430T3 (ko)
HK (1) HK1062170A1 (ko)
HU (1) HUP0303811A3 (ko)
IL (1) IL157881A0 (ko)
MX (1) MXPA03009527A (ko)
PL (1) PL366657A1 (ko)
PT (1) PT1383733E (ko)
RU (1) RU2282619C9 (ko)
TW (1) TWI244472B (ko)
WO (1) WO2002085843A2 (ko)
YU (1) YU78303A (ko)
ZA (1) ZA200307205B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234268D1 (de) * 2001-11-16 2009-12-17 Cdt Oxford Ltd Leuchtdiode und verwendete verbindungen
MXPA05005517A (es) * 2002-11-25 2005-07-25 Pfizer Prod Inc Procedimiento mejorado para la preparacion de indenos 1,3-disustituidos.
RU2291862C2 (ru) * 2003-01-15 2007-01-20 Пфайзер Продактс Инк. Способ получения арилконденсированных полициклических лактамов
MXPA05013084A (es) * 2003-06-04 2006-03-02 Pfizer Prod Inc Preparacion de quinoxalinas sustituidas a partir de la dianilina con 2,3-dihidroxi-1,4-dioxano.
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
DE602006013688D1 (de) * 2005-11-16 2010-05-27 Hoffmann La Roche Neues verfahren zur herstellung von thoc
DE102006024903A1 (de) * 2006-05-24 2007-11-29 Basf Ag Verfahren zur Vermeidung von Fumarsäureablagerungen bei der Herstellung von Maleinsäureanhydrid
RS52074B (en) * 2007-05-16 2012-06-30 Nycomed Gmbh PIRAZOLONE DERIVATED AS PDE4 INHIBITORS
EP2019107A1 (en) 2007-07-26 2009-01-28 Dynamit Nobel GmbH Explosivstoff- und Systemtechnik Use of phosphonium salts in coupling reactions and process for their manufacture
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
WO2009101185A2 (en) * 2008-02-15 2009-08-20 Medichem, S.A. A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010151524A1 (en) 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
KR101603427B1 (ko) * 2014-08-14 2016-03-15 영남대학교 산학협력단 케스케이드 반응을 통한 인덴 유도체의 효율적 합성방법
CN104478803A (zh) * 2014-12-19 2015-04-01 连云港恒运医药科技有限公司 伐尼克兰中间体及其硝基还原杂质的制备方法
JP6956707B2 (ja) * 2015-08-14 2021-11-02 ボウロス アンド クーパー ファーマスーティカルズ プロプライエタリー リミテッドＢｏｕｌｏｓ ＆ Ｃｏｏｐｅｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｐｔｙ Ｌｔｄ アリール化合物の合成
US11084853B2 (en) 2016-07-07 2021-08-10 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
WO2019094778A1 (en) 2017-11-10 2019-05-16 Scott Sternson Modified ligand-gated ion channels and methods of use
CN111995519B (zh) * 2020-09-26 2022-08-26 安徽金禾实业股份有限公司 一种3-甲氧基丙烯酸甲酯的制备方法
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479598A (en) * 1992-10-23 1995-12-26 International Business Machines Corporation Compact graphical parallel program user output interface controlled directly by the parallel computer program
DE69409445D1 (de) * 1993-07-27 1998-05-14 Ibm Prozessüberwachung in einem Mehrfachverarbeitungsanbieter
US6289368B1 (en) * 1995-12-27 2001-09-11 First Data Corporation Method and apparatus for indicating the status of one or more computer processes
US5928323A (en) * 1996-05-30 1999-07-27 Sun Microsystems, Inc. Apparatus and method for dynamically generating information with server-side software objects
FR2751448B1 (fr) * 1996-07-17 1999-01-15 Bull Sa Procede de surveillance en temps reel d'un systeme informatique pour son administration et l'aide a sa maintenance en phase d'exploitation
US6112194A (en) * 1997-07-21 2000-08-29 International Business Machines Corporation Method, apparatus and computer program product for data mining having user feedback mechanism for monitoring performance of mining tasks
US6119165A (en) * 1997-11-17 2000-09-12 Trend Micro, Inc. Controlled distribution of application programs in a computer network
US6100887A (en) * 1997-12-05 2000-08-08 At&T Corporation Reusable reversible progress indicator software component for a graphical user interface
CN1324013C (zh) * 1997-12-31 2007-07-04 辉瑞产品公司 芳基稠合氮杂多环化合物
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
US6151357A (en) * 1998-01-16 2000-11-21 Aspect Communications Corporation Method and apparatus for displaying a visual indication of a transmission status
US6108003A (en) * 1998-03-18 2000-08-22 International Business Machines Corporation Maintaining visibility and status indication of docked applications and application bars
CA2330576A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Substituted benzazocines as nicotine-binding inhibitors
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
EP1194399A2 (en) * 1999-07-02 2002-04-10 Prescient Neuropharma Inc. Novel aminoindanes
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)

Also Published As

Publication number Publication date
KR100551183B1 (ko) 2006-02-13
PL366657A1 (en) 2005-02-07
CN1503781A (zh) 2004-06-09
AR035957A1 (es) 2004-07-28
JP2004527545A (ja) 2004-09-09
PT1383733E (pt) 2008-04-15
HUP0303811A2 (hu) 2004-03-01
CZ20032814A3 (cs) 2004-08-18
WO2002085843A2 (en) 2002-10-31
ATE388135T1 (de) 2008-03-15
WO2002085843A3 (en) 2003-06-05
KR20030092087A (ko) 2003-12-03
EP1383733A2 (en) 2004-01-28
US20060079707A1 (en) 2006-04-13
RU2003130751A (ru) 2005-03-27
YU78303A (sh) 2006-05-25
DE60225433D1 (de) 2008-04-17
ES2300430T3 (es) 2008-06-16
ZA200307205B (en) 2004-09-15
DE60225433T2 (de) 2008-06-12
US7186870B2 (en) 2007-03-06
TWI244472B (en) 2005-12-01
CN1321107C (zh) 2007-06-13
HUP0303811A3 (en) 2008-05-28
AU2002234836B2 (en) 2007-08-23
US7091372B2 (en) 2006-08-15
DK1383733T3 (da) 2008-06-09
BR0208992A (pt) 2004-04-27
RU2282619C9 (ru) 2006-12-20
CA2443946A1 (en) 2002-10-31
US20030060624A1 (en) 2003-03-27
AR043636A2 (es) 2005-08-03
HK1062170A1 (en) 2004-10-21
EP1383733B1 (en) 2008-03-05
RU2282619C2 (ru) 2006-08-27
MXPA03009527A (es) 2004-02-12

Similar Documents

Publication Publication Date Title
IL157881A0 (en) Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
HUP9900163A3 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
IL143106A (en) Process for the preparation of diphenylmethylthioacetamide
IL129906A0 (en) Process for the preparation of beta-isophorone
IL157709A0 (en) Process for the preparation of 1,2-benzisoxazole-3-acetic acid
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
GB2343892B (en) Process for the preparation of d,l-menthol
EP1191015A4 (en) AMINO STYRENE R THEN DERIVATIVES, INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND METHOD FOR THE PRODUCTION OF BOTH
HUP0402475A3 (en) Process for the preparation of [1,4,5]-oxadiazepine derivatives
HK1066022A1 (en) Use of 1,1,1,3,3-pentafluorobutan
PL377292A1 (pl) Ulepszony sposób wytwarzania 1,3-podstawionych indenów
HUP0303025A3 (en) Process for the preparation of arylethanoldiamines
EP1295864A4 (en) PROCESS FOR THE PREPARATION OF 1,5-DIAMINONAPHTHALINES
IL137364A (en) Process for the preparation of 6,6-dimethylhept-1-en-4-yn-3-ol
MXPA03009210A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE OXABISPIDINAS.
SG95675A1 (en) Process for the preparation of 2,6-xylenol
IL141947A0 (en) Process for the preparation of 4,4'-dihalogen-o-hydroxydiphenyl compounds
HUP9902745A2 (en) Process for the preparation of benzylcarbazate
PL344141A1 (en) Process for preparation of 4,5-epoxymorphinan-6-oxyglucuronides
PL368905A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
HK1041606B (zh) N，n'-羰基雙內酰胺的製備方法
IL153935A0 (en) Process for the preparation of chiral 1,4-diaryl-2-fluoro-2-butenes
AU2002315953A1 (en) Process for the preparation of 2,4-dideoxyhexoses and 2,4,6-trideoxyhexoses